
Jonathan P Segal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7021778/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	12.1	793
2	The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67, 1920-1941.	12.1	248
3	The gut virome: the â€~missing link' between gut bacteria and host immunity?. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481983662.	3.2	127
4	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	8.1	111
5	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	12.1	110
6	Systematic review with metaâ€analysis: the management of chronic refractory pouchitis with an evidenceâ€based treatment algorithm. Alimentary Pharmacology and Therapeutics, 2017, 45, 581-592.	3.7	91
7	Ulcerative colitis: an update. Clinical Medicine, 2021, 21, 135-139.	1.9	87
8	Bacteroides thetaiotaomicron-derived outer membrane vesicles promote regulatory dendritic cell responses in health but not in inflammatory bowel disease. Microbiome, 2020, 8, 88.	11.1	76
9	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2021, 6, 826-849.	8.1	69
10	Deficient Resident Memory T Cell and CD8 T Cell Response to Commensals in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 525-537.	1.3	60
11	The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097491.	3.2	50
12	The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481882225.	3.2	49
13	Vitamin D Therapy in Adults With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases, 2020, 26, 1819-1830.	1.9	42
14	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2022, 7, 69-95.	8.1	41
15	The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Journal of Hospital Infection, 2018, 100, S1-S31.	2.9	38
16	Systematic review: ileoanal pouch microbiota in health and disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 466-477.	3.7	38
17	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. Journal of Crohn's and Colitis, 2021, 15, 1184-1196.	1.3	26
18	Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 735-743.	1.3	24

#	Article	IF	CITATIONS
19	Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis. Frontline Gastroenterology, 2018, 9, 154-158.	1.8	23
20	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23
21	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094690.	3.2	21
22	The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis. Nutrients, 2021, 13, 1780.	4.1	21
23	National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK. Journal of Hospital Infection, 2017, 95, 444-445.	2.9	20
24	A Systematic Review: The Management and Outcomes of Ileal Pouch Strictures. Journal of Crohn's and Colitis, 2018, 12, 369-375.	1.3	20
25	The Incidence and Prevalence of Human Papilloma Virus–associated Cancers in IBD. Inflammatory Bowel Diseases, 2021, 27, 34-39.	1.9	19
26	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. Future Microbiology, 2020, 15, 1173-1183.	2.0	18
27	Colectomy rates for ulcerative colitis in England 2003â€⊋016. Alimentary Pharmacology and Therapeutics, 2021, 53, 484-498.	3.7	18
28	The Renew® anal insert for passive faecal incontinence: a retrospective audit of our use of a novel device. Colorectal Disease, 2019, 21, 684-688.	1.4	17
29	The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterology, 2021, 12, 118-127.	1.8	16
30	Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989103.	3.2	15
31	Incidence and Long-term Implications of Prepouch Ileitis: An Observational Study. Diseases of the Colon and Rectum, 2018, 61, 472-475.	1.3	14
32	Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines. Journal of Hospital Infection, 2018, 100, 130-132.	2.9	14
33	Acceptability, effectiveness and safety of a Renew [®] anal insert in patients who have undergone restorative proctocolectomy with ileal pouch–anal anastomosis. Colorectal Disease, 2019, 21, 73-78.	1.4	13
34	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Annals of Gastroenterology, 2020, 33, 170-177.	0.6	13
35	Prevalence of †pouch failure' of the ileoanal pouch in ulcerative colitis: a systematic review and meta-analysis. International Journal of Colorectal Disease, 2022, 37, 357-364.	2.2	13
36	A review of the therapeutic management of Crohn's disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210784.	3.2	13

#	Article	IF	CITATIONS
37	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. Scandinavian Journal of Gastroenterology, 2018, 53, 1051-1058.	1.5	12
38	COVID-19 vaccinations in patients with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 965-966.	8.1	12
39	Inflammatory bowel disease patientâ€reported quality assessment should drive service improvement: a national survey of <scp>UK IBD</scp> units and patients. Alimentary Pharmacology and Therapeutics, 2022, 56, 625-645.	3.7	12
40	How to manage IBD in the â€~elderly'. Frontline Gastroenterology, 2020, 11, 468-477.	1.8	11
41	Training in endotherapy for acute upper gastrointestinal bleeding: a UK-wide gastroenterology trainee survey. Frontline Gastroenterology, 2020, 11, 430-435.	1.8	11
42	Oral and Intravenous Iron Therapy Differentially Alter the On- and Off-Tumor Microbiota in Anemic Colorectal Cancer Patients. Cancers, 2021, 13, 1341.	3.7	11
43	Microbiome: what intensivists should know. Minerva Anestesiologica, 2020, 86, 777-785.	1.0	11
44	Prevalence of pouchitis in both ulcerative colitis and familial adenomatous polyposis: A systematic review and metaâ€analysis. Colorectal Disease, 2022, 24, 27-39.	1.4	11
45	Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience. Scandinavian Journal of Gastroenterology, 2018, 53, 665-669.	1.5	10
46	Management of early pouchâ€related septic complications in ulcerative colitis: a systematic review. Colorectal Disease, 2018, 20, O181-O189.	1.4	9
47	STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis. BMJ Open, 2019, 9, e030659.	1.9	9
48	Letter: faecal microbiota transplantation for IBS. Alimentary Pharmacology and Therapeutics, 2020, 52, 556-557.	3.7	8
49	Inflammatory bowel disease in India: challenges and opportunities. Frontline Gastroenterology, 2021, 12, 390-396.	1.8	8
50	Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD. BMJ Open Gastroenterology, 2021, 8, e000603.	2.7	8
51	The impact of the ileoanal pouch on female fertility in ulcerative colitis: A systematic review and metaâ€analysis. Colorectal Disease, 2022, 24, 918-924.	1.4	8
52	Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers. Clinical and Experimental Gastroenterology, 2018, Volume 11, 461-465.	2.3	7
53	Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11, 100045.	3.8	7
54	Medical images, social media and consent. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 517-518.	17.8	7

#	Article	IF	CITATIONS
55	The public's attitude towards doctors' use of Twitter and perceived professionalism: an exploratory study. Clinical Medicine, 2021, 21, e475-e479.	1.9	7
56	Letter: risk of severe COVIDâ€19 outcomes associated with inflammatory bowel disease medications—reassuring insights from the United Kingdom PREPAREâ€IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1236-1240.	3.7	7
57	Stroke mimic: an interesting case of repetitive conversion disorder. BMJ Case Reports, 2012, 2012, bcr2012007556.	0.5	6
58	Does the Internet promote the unregulated use of fecal microbiota transplantation: a potential public health issue?. Clinical and Experimental Gastroenterology, 2018, Volume 11, 179-183.	2.3	6
59	Are we addressing the top 10 research priorities in IBD?. Frontline Gastroenterology, 2021, 12, 564-569.	1.8	6
60	Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment. Frontline Gastroenterology, 2022, 13, 168-170.	1.8	6
61	lleoanal pouch cancers in ulcerative colitis and familial adenomatous polyposis: A systematic review and meta-analysis. Digestive and Liver Disease, 2022, 54, 1328-1334.	0.9	6
62	Changing patterns of heroin and crack use during pregnancy and beyond. Journal of Substance Use, 2009, 14, 124-132.	0.7	5
63	The pouch behaving badly: management of morbidity after ileal pouch–anal anastomosis. Colorectal Disease, 2021, 23, 1193-1204.	1.4	5
64	What next for gastroenterology and hepatology trainee networks? Lessons from our surgical colleagues. Frontline Gastroenterology, 2022, 13, 82-85.	1.8	5
65	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	8.1	5
66	Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1236-1240.	3.7	5
67	Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2022, 34, 518-528.	1.6	5
68	Achalasia leading to diagnosis of adenocarcinoma of the oesophagus. BMJ Case Reports, 2017, 2017, bcr-2017-219386.	0.5	4
69	Inflammatory bowel disease advice lines during the COVID-19 pandemic: a retrospective service evaluation. Gastrointestinal Nursing, 2021, 19, 38-49.	0.1	4
70	An Unusual Cause of Gastrointestinal Perforation in an Adolescent Patient With Beta-Thalassemia on Deferasirox and SARS-CoV-2 Infection. Journal of Hematology (Brossard, Quebec), 2021, 10, 76-79.	1.0	4
71	Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterology, 2022, 9, e000763.	2.7	4
72	The impact of COVID-19 on endoscopy training needs to be considered in the context of a global pandemic. Gastrointestinal Endoscopy, 2020, 92, 1146-1147.	1.0	3

#	Article	IF	CITATIONS
73	Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting. GastroHep, 2020, 2, 309-317.	0.6	3
74	Quality of care in adult patients with inflammatory bowel disease transferring between healthcare providers: multicentre audit. Frontline Gastroenterology, 2021, 12, 5-10.	1.8	3
75	Crohn's Disease in theÂlleal Pouch Anal Anastomosis: Management Strategies. , 2019, , 91-103.		2
76	Diversion colitis: Aetiology, diagnosis and treatment. A systematic review. GastroHep, 2020, 2, 266-271.	0.6	2
77	Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVIDâ€19 in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2020, 52, 937-939.	3.7	2
78	Implications of recurrent SARS-CoV-2 outbreaks for IBD management. Frontline Gastroenterology, 2021, 12, 316-321.	1.8	2
79	Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterology, 2022, 13, 77-81.	1.8	2
80	Prevention of COVID-19 in patients with IBD. The Lancet Gastroenterology and Hepatology, 2020, 5, 639-640.	8.1	2
81	New Ultra Low Volume Bowel Preparation and Overview of Existing Bowel Preparations. Current Drug Metabolism, 2020, 21, 844-849.	1.2	2
82	Variability in the Pre-Analytical Stages Influences Microbiome Laboratory Analyses. Genes, 2022, 13, 1069.	2.4	2
83	PWE-052â€Long term outcomes of initial IFX therapy for inflammatory pouch pathology: a multi-centre retrospective study. , 2018, , .		1
84	Polyp detection rate: does length matter?. Frontline Gastroenterology, 2019, 10, 107-112.	1.8	1
85	IDDF2019-ABS-0028â€Mucosal tissue short chain fatty acids contribute to prediction of pouchitis in restorative proctocolectomy. , 2019, , .		1
86	Interesting case of dual pathology: Crohn's disease and Peutz-Jeghers syndrome. BMJ Case Reports, 2020, 13, e234513.	0.5	1
87	Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis. United European Gastroenterology Journal, 2021, 9, 127-127.	3.8	1
88	O9â€STOP-colitis pilot: prospective, open-label, randomised study comparing nasogastric versus colonic FMT delivery in ulcerative colitis. , 2021, , .		1
89	Squamous cell carcinoma at the site of ileo-anal pouch in Crohn's disease. BMJ Case Reports, 2021, 14, e237438.	0.5	1
90	The ileoanal pouch: the next frontier in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 164-165.	8.1	1

#	Article	IF	CITATIONS
91	The impact of SARS-CoV-2 variants on IBD management. The Lancet Gastroenterology and Hepatology, 2021, 6, 343-344.	8.1	1
92	Intestinal ultrasonography: a useful skill for efficient, non-invasive monitoring of patients with IBD using a clinic-based point-of-care approach. Frontline Gastroenterology, 2022, 13, 447-451.	1.8	1
93	IDDF2021-ABS-0105â€Prevalence of â€~pouch failure' of the ileoanal pouch in ulcerative colitis: a systemati review and meta-analysis. , 2021, , .	C	1
94	Letter: normalising the ileoanal pouch—more than a oneâ€step technique. Alimentary Pharmacology and Therapeutics, 2022, 56, 174-175.	3.7	1
95	Intestinal Failure: A Rare but Significant Outcome of Restorative Proctocolectomy. Gastroenterology, 2017, 152, S271.	1.3	0
96	Current Practices in Ileal Pouch Surveillance for Ulcerative Colitis Patients in Three London IBD Referral Centres. Gastroenterology, 2017, 152, S377.	1.3	0
97	PTU-061â€Efficacy and acceptability of a renew anal insert in patients who have undergone restorative proctocolectomy. , 2018, , .		0
98	PWE-051â€Biological therapy for the treatment of pre-pouch ileitis: a retrospective experience from three centres. , 2018, , .		0
99	OWE-024â€The natural history of terminal ileal resection in crohnâ \in ™s disease. , 2018, , .		0
100	PTU-062â€Systematic review: the management of early pouch-related septic complications in ulcerative colitis. , 2018, , .		0
101	IDDF2018-ABS-0057â€Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience. , 2018, , .		0
102	IDDF2018-ABS-0056â€Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study. , 2018, , .		0
103	IDDF2018-ABS-0055â€The natural history of terminal ileal resection in crohn's disease. , 2018, , .		0
104	PWE-009â€The accuracy of faecal calprotectin measurement from stoma effluent in predicting crohn's disease activity. , 2018, , .		0
105	PWE-053â€Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience. , 2018, , .		0
106	Twenty years of biological therapy in an patient with IBD. BMJ Case Reports, 2018, 2018, bcr-2017-221994.	0.5	0
107	PTU-060â€Management of pouch strictures in restorative proctocolectomy. a tertiary centre experience with a treatment algorithm. , 2018, , .		0
108	The Role of Biomarkers in theÂlleal Anal Pouch. , 2019, , 169-180.		0

108 The Role of Biomarkers in theÂlleal Anal Pouch. , 2019, , 169-180.

#	Article	IF	CITATIONS
109	PTH-118â€Mucosal tissue short chain fatty acids contribute to prediction of pouchitis in restorative proctocolectomy. , 2019, , .		Ο
110	IDDF2019-ABS-0027â€Urinary formate and glycine are associated with treatment response in patients treated with antibiotics for pouchitis. , 2019, , .		0
111	HPV-related Cancers in Inflammatory Bowel Disease: Association Not Yet Causation. Inflammatory Bowel Diseases, 2020, 26, e102-e102.	1.9	0
112	P123â€Are we addressing the top ten research priorities in management of IBD in the UK?. , 2021, , .		0
113	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 147-163.	0.9	0
114	Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis. United European Gastroenterology Journal, 2021, 9, 279-279.	3.8	0
115	Clinical, biomarker and endoscopic outcomes in patients with Crohn's disease treated with Ustekinumab: Multiâ€centre real world study. GastroHep, 2021, 3, 151-160.	0.6	Ο
116	DOP37 Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey. Journal of Crohn's and Colitis, 2021, 15, S075-S076.	1.3	0
117	IDDF2021-ABS-0117â€Prevalence of pouchitis in both ulcerative colitis and familial adenomatous polyposis; a systematic review and meta-analysis. , 2021, , .		Ο
118	P101â€Discontinuation of ustekinumab in patients with Crohn's disease: multi-centre real world data. , 2021, , .		0
119	P148â€An intervention bundle leads to quality improvement in endoscopic reporting of ulcerative colitis. , 2021, , .		Ο
120	Dual Anti-Platelet Therapy and Gastrointestinal Protection Audit. American Journal of Gastroenterology, 2012, 107, S116.	0.4	0
121	Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 733-734.	3.7	Ο
122	ATU-3â€Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD. , 2021, , .		0
123	ATU-9â€Ambulatory care management of 70 patients with acute severe UC in comparison to 700 inpatients. , 2021, , .		Ο
124	PTH-104â€Comparing the characteristics of colorectal cancer in young versus old patients. , 2021, , .		0
125	HMO-1â€Variation in IBD care and education across Europe results from a pan-European survey. , 2021, , .		0
126	HTH-14â€A multi-centre analysis of AUGIB; urea-creatinine ratiois a useful predictor for bleeding, and endotherapy. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
127	Inflammatory disease of the ileoanal pouch –Âis it all in the microbiome?. Future Microbiology, 2022, 17, 481-483.	2.0	Ο
128	Personalised medicine in IBD: don't dispose of the sledgehammer just yet. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210925.	3.2	0
129	Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis. United European Gastroenterology Journal, 2021, , .	3.8	0